An RBC Capital analyst noted that while MariTide’s efficacy aligns with the brokerage’s expectations, its tolerability and long-term dosing regimen leave room for improvement.
Amgen’s weight-loss drug candidate MariTide is meant to be administered subcutaneously monthly or less frequently in obese or overweight patients without Type 2 diabetes.
he new proposal would expand access to medications for obesity, and help an estimated 3.4 million Americans with Medicare.
Replimune’s lead asset RP1 is based on a proprietary new strain of Herpes simplex virus engineered to maximize tumor killing potency.
/Bio-Techne%20Corp%20sign-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Bio-Techne has underperformed the broader market over the past year, yet analysts remain bullish on the stock’s prospects.
The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup.
Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.
Trump said his HHS Secretary nominee will ensure the public is protected from harmful substances that have aggravated the nation’s health crisis.
Less stringent requirements in pharmaceuticals and biotechnology could help biotechs by prompting accelerated drug approvals.
Altimmune said its obesity drug candidate is highly differentiated from other incretin-based agents currently available and in development.